The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Bipolar Disorders and Treatment-Global Market Insights and Sales Trends 2024

Bipolar Disorders and Treatment-Global Market Insights and Sales Trends 2024

Publishing Date : Nov, 2023

License Type :
 

Report Code : 1835920

No of Pages : 88

Synopsis
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks.
The global Bipolar Disorders and Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Bipolar Disorders and Treatment in various end use industries. The expanding demands from the Hospital, Pharmacy and Other, are propelling Bipolar Disorders and Treatment market. Mood Stabilizer, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anticonvulsant segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Sale Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bipolar Disorders and Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bipolar Disorders and Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bipolar Disorders and Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bipolar Disorders and Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bipolar Disorders and Treatment covered in this report include GlaxoSmithKline, Pfizer, Janssen Pharmaceuticals, Eli Lilly, Allergan, Novartis, ​​AbbVie, Otsuka Holdings and AstraZeneca, etc.
The global Bipolar Disorders and Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Pfizer
Janssen Pharmaceuticals
Eli Lilly
Allergan
Novartis
​​AbbVie
Otsuka Holdings
AstraZeneca
Global Bipolar Disorders and Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bipolar Disorders and Treatment market, Segment by Type:
Mood Stabilizer
Anticonvulsant
Antipsychotic
Antidepressant
Antianxiety
Global Bipolar Disorders and Treatment market, by Sale Channel
Hospital
Pharmacy
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Sale Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Bipolar Disorders and Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index
1 Market Overview of Bipolar Disorders and Treatment
1.1 Bipolar Disorders and Treatment Market Overview
1.1.1 Bipolar Disorders and Treatment Product Scope
1.1.2 Bipolar Disorders and Treatment Market Status and Outlook
1.2 Global Bipolar Disorders and Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Bipolar Disorders and Treatment Market Size by Region (2018-2029)
1.4 Global Bipolar Disorders and Treatment Historic Market Size by Region (2018-2023)
1.5 Global Bipolar Disorders and Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Bipolar Disorders and Treatment Market Size (2018-2029)
1.6.1 North America Bipolar Disorders and Treatment Market Size (2018-2029)
1.6.2 Europe Bipolar Disorders and Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Bipolar Disorders and Treatment Market Size (2018-2029)
1.6.4 Latin America Bipolar Disorders and Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Bipolar Disorders and Treatment Market Size (2018-2029)
2 Bipolar Disorders and Treatment Market by Type
2.1 Introduction
2.1.1 Mood Stabilizer
2.1.2 Anticonvulsant
2.1.3 Antipsychotic
2.1.4 Antidepressant
2.1.5 Antianxiety
2.2 Global Bipolar Disorders and Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Bipolar Disorders and Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Bipolar Disorders and Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Bipolar Disorders and Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Bipolar Disorders and Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Bipolar Disorders and Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Bipolar Disorders and Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Bipolar Disorders and Treatment Revenue Breakdown by Type (2018-2029)
3 Bipolar Disorders and Treatment Market Overview by Sale Channel
3.1 Introduction
3.1.1 Hospital
3.1.2 Pharmacy
3.1.3 Other
3.2 Global Bipolar Disorders and Treatment Market Size by Sale Channel: 2018 VS 2022 VS 2029
3.2.1 Global Bipolar Disorders and Treatment Historic Market Size by Sale Channel (2018-2023)
3.2.2 Global Bipolar Disorders and Treatment Forecasted Market Size by Sale Channel (2024-2029)
3.3 Key Regions Market Size by Sale Channel
3.3.1 North America Bipolar Disorders and Treatment Revenue Breakdown by Sale Channel (2018-2029)
3.3.2 Europe Bipolar Disorders and Treatment Revenue Breakdown by Sale Channel (2018-2029)
3.3.3 Asia-Pacific Bipolar Disorders and Treatment Revenue Breakdown by Sale Channel (2018-2029)
3.3.4 Latin America Bipolar Disorders and Treatment Revenue Breakdown by Sale Channel (2018-2029)
3.3.5 Middle East and Africa Bipolar Disorders and Treatment Revenue Breakdown by Sale Channel (2018-2029)
4 Bipolar Disorders and Treatment Competition Analysis by Players
4.1 Global Bipolar Disorders and Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bipolar Disorders and Treatment as of 2022)
4.3 Date of Key Players Enter into Bipolar Disorders and Treatment Market
4.4 Global Top Players Bipolar Disorders and Treatment Headquarters and Area Served
4.5 Key Players Bipolar Disorders and Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Bipolar Disorders and Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline Profile
5.1.2 GlaxoSmithKline Main Business
5.1.3 GlaxoSmithKline Bipolar Disorders and Treatment Products, Services and Solutions
5.1.4 GlaxoSmithKline Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 GlaxoSmithKline Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Bipolar Disorders and Treatment Products, Services and Solutions
5.2.4 Pfizer Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Janssen Pharmaceuticals
5.3.1 Janssen Pharmaceuticals Profile
5.3.2 Janssen Pharmaceuticals Main Business
5.3.3 Janssen Pharmaceuticals Bipolar Disorders and Treatment Products, Services and Solutions
5.3.4 Janssen Pharmaceuticals Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Eli Lilly Recent Developments
5.4 Eli Lilly
5.4.1 Eli Lilly Profile
5.4.2 Eli Lilly Main Business
5.4.3 Eli Lilly Bipolar Disorders and Treatment Products, Services and Solutions
5.4.4 Eli Lilly Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Eli Lilly Recent Developments
5.5 Allergan
5.5.1 Allergan Profile
5.5.2 Allergan Main Business
5.5.3 Allergan Bipolar Disorders and Treatment Products, Services and Solutions
5.5.4 Allergan Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Allergan Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Bipolar Disorders and Treatment Products, Services and Solutions
5.6.4 Novartis Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 ​​AbbVie
5.7.1 ​​AbbVie Profile
5.7.2 ​​AbbVie Main Business
5.7.3 ​​AbbVie Bipolar Disorders and Treatment Products, Services and Solutions
5.7.4 ​​AbbVie Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 ​​AbbVie Recent Developments
5.8 Otsuka Holdings
5.8.1 Otsuka Holdings Profile
5.8.2 Otsuka Holdings Main Business
5.8.3 Otsuka Holdings Bipolar Disorders and Treatment Products, Services and Solutions
5.8.4 Otsuka Holdings Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Otsuka Holdings Recent Developments
5.9 AstraZeneca
5.9.1 AstraZeneca Profile
5.9.2 AstraZeneca Main Business
5.9.3 AstraZeneca Bipolar Disorders and Treatment Products, Services and Solutions
5.9.4 AstraZeneca Bipolar Disorders and Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 AstraZeneca Recent Developments
6 North America
6.1 North America Bipolar Disorders and Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Bipolar Disorders and Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Bipolar Disorders and Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Bipolar Disorders and Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Bipolar Disorders and Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Bipolar Disorders and Treatment Market Dynamics
11.1 Bipolar Disorders and Treatment Industry Trends
11.2 Bipolar Disorders and Treatment Market Drivers
11.3 Bipolar Disorders and Treatment Market Challenges
11.4 Bipolar Disorders and Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’